|
|
Vaccine Detail
|
ALVAC-MART-1 Vaccine |
| Vaccine Information |
- Vaccine Name: ALVAC-MART-1 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007247
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- MLANA
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: Parental ALVAC, recombinant ALVAC containing the Lac-Z gene (ALVAC-β-gal, vCP 326), and ALVAC vectors carry DNA sequences coding for MART-1 (vCP 1467) or melanoma gp100 (vCP 1465). Viral vectors were added to the DC (106 cells/ml in RPMI 1640 supplemented with 2% FCS) at a multiplicity of infection (moi) of 10 or 30. The infection was conducted at 37°C for 1 h, following which the infected DC were washed twice in complete FCS 10 medium. Infected DC were recultured for 3–18 h, as specified (Motta et al., 2001).
- Description: A cancer vaccine containing a replication-defective recombinant canarypox virus (ALVAC), encoding an epitope of MART-1 (melanoma antigen recognized by T-cells), with potential immunostimulatory and antineoplastic activities. Upon administration, the MART-1 epitope is expressed by the ALVAC vector in ALVAC-MART-1 vaccine; a host cytotoxic T lymphocyte (CTL) response against MART-1-expressing tumor cells may follow, resulting in tumor cell lysis and decreased tumor cell proliferation (NCIT_C73999).
This vaccine has been used in advanced melanoma patients. NCT00612222
|
| Host Response |
|
|
| References |
Motta et al., 2001: Motta I, André F, Lim A, Tartaglia J, Cox WI, Zitvogel L, Angevin E, Kourilsky P. Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. Journal of immunology (Baltimore, Md. : 1950). 2001; 167(3); 1795-1802. [PubMed: 11466405].
NCIT_C73999: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C73999]
|
|
